Researchers at Mass General Brigham have identified a genetic variant that may provide protection against early-onset Alzheimer's disease, potentially paving the way for new therapeutic avenues. The study, published in The New England Journal of Medicine, focuses on families with a predisposition to Alzheimer's due to genetic mutations such as the Paisa mutation (Presenilin-1 E280A).
The research highlights a variant on the APOE3 gene known as Christchurch (APOE3Ch), which appears to delay the onset of cognitive decline in individuals genetically susceptible to Alzheimer's. By analyzing data from descendants of a Colombian family with the Paisa mutation, researchers found that those carrying both the Paisa mutation and one copy of the Christchurch variant showed signs of dementia, on average, four years later than those without the Christchurch variant.
Yakeel T. Quiroz, PhD, from Massachusetts General Hospital, underscores the potential implications for developing treatments that target APOE-related pathways. The findings offer optimism for delaying dementia onset and underscore the importance of understanding genetic variants in Alzheimer's disease management and treatment planning.
This breakthrough not only sheds light on protective mechanisms against early-onset Alzheimer's but also highlights the necessity of broader genetic studies to explore these effects across different populations and Alzheimer's subtypes.
The research highlights a variant on the APOE3 gene known as Christchurch (APOE3Ch), which appears to delay the onset of cognitive decline in individuals genetically susceptible to Alzheimer's. By analyzing data from descendants of a Colombian family with the Paisa mutation, researchers found that those carrying both the Paisa mutation and one copy of the Christchurch variant showed signs of dementia, on average, four years later than those without the Christchurch variant.
Yakeel T. Quiroz, PhD, from Massachusetts General Hospital, underscores the potential implications for developing treatments that target APOE-related pathways. The findings offer optimism for delaying dementia onset and underscore the importance of understanding genetic variants in Alzheimer's disease management and treatment planning.
This breakthrough not only sheds light on protective mechanisms against early-onset Alzheimer's but also highlights the necessity of broader genetic studies to explore these effects across different populations and Alzheimer's subtypes.
About this article
From the Medical Directory library. For advice about your own health, speak to your healthcare professional.
JOIN THE CONVERSATION
No comments yet. Add a thoughtful question or comment about this article.